Skip to main content
Erschienen in: The Cerebellum 6/2015

01.12.2015 | Original Paper

Epidemiology of Multiple System Atrophy in Hokkaido, the Northernmost Island of Japan

verfasst von: Ken Sakushima, Naoki Nishimoto, Masanori Nojima, Masaaki Matsushima, Ichiro Yabe, Norihiro Sato, Mitsuru Mori, Hidenao Sasaki

Erschienen in: The Cerebellum | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Multiple system atrophy (MSA) is an intractable neurodegenerative disorder that is characterized by various combinations of autonomic failure, cerebellar ataxia, and parkinsonism. We conducted an epidemiological study of MSA using the combined data of a national registry system and a postal survey in Hokkaido, Japan. A postal survey was conducted in 2013 based on national registry data from 2006 to 2011. This survey contained the current status of each patient with MSA that had been collected from attending physicians and recorded into a national registry. Survey items included date, outcomes, primary symptoms, and activities of daily living at the last medical examination. Confirmation data of the diagnosis by a board-certified neurologist was also collected. Based on the national registry data, 1,092 patients with MSA were selected as our target population. The response rate of the postal survey was 81 % (885/1,092). After excluding inappropriate responses, 839 patients with MSA were analyzed. Forty-nine percent of the patients were male, and the mean onset age was 62.1 ± 10.4 years. A Kaplan-Meier survival curve revealed that patients with onset symptoms of cerebellar ataxia had a better prognosis than those with onset of parkinsonism or autonomic failure (p < 0.01). Additionally, we found that a higher onset age was associated with poor prognosis. We found that patients with cerebellar ataxia at onset had a better survival prognosis than those with parkinsonism or autonomic failure at onset and that patients with an older age at onset had a worse survival prognosis.
Literatur
1.
Zurück zum Zitat Quinn N. Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatr. 1989; Suppl.:78–89. Quinn N. Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatr. 1989; Suppl.:78–89.
2.
Zurück zum Zitat Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.CrossRefPubMed Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.CrossRefPubMed
3.
Zurück zum Zitat Colosimo C. Nonmotor presentations of multiple system atrophy. Nat Rev Neurol. 2011;7(5):295–8.CrossRefPubMed Colosimo C. Nonmotor presentations of multiple system atrophy. Nat Rev Neurol. 2011;7(5):295–8.CrossRefPubMed
4.
Zurück zum Zitat Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25(15):2604–12.CrossRefPubMed Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25(15):2604–12.CrossRefPubMed
5.
Zurück zum Zitat Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(Pt 5):1070–83.CrossRefPubMed Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(Pt 5):1070–83.CrossRefPubMed
6.
Zurück zum Zitat Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, Sasaki H. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci. 2006;249(2):115–21.CrossRefPubMed Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, Sasaki H. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci. 2006;249(2):115–21.CrossRefPubMed
7.
Zurück zum Zitat Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264–74.PubMedCentralCrossRefPubMed Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264–74.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm. 2005;112(12):1677–86.CrossRefPubMed Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm. 2005;112(12):1677–86.CrossRefPubMed
9.
Zurück zum Zitat Hirayama K, Takayanagi T, Nakamura R, Yanagisawa N, Hattori T, Kita K, et al. Spinocerebellar degenerations in Japan: a nationwide epidemiological and clinical study. Acta Neurol Scand Suppl. 1994;153:1–22.CrossRefPubMed Hirayama K, Takayanagi T, Nakamura R, Yanagisawa N, Hattori T, Kita K, et al. Spinocerebellar degenerations in Japan: a nationwide epidemiological and clinical study. Acta Neurol Scand Suppl. 1994;153:1–22.CrossRefPubMed
10.
Zurück zum Zitat Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum. 2008;7(2):189–97.CrossRefPubMed Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum. 2008;7(2):189–97.CrossRefPubMed
11.
Zurück zum Zitat Collaboration TM-SAR. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369(3):233–44.CrossRef Collaboration TM-SAR. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369(3):233–44.CrossRef
12.
Zurück zum Zitat Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.PubMedCentralCrossRefPubMed Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;68(4):434–40.PubMedCentralCrossRefPubMed Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;68(4):434–40.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiol. 2004;23(4):201–8.CrossRef Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiol. 2004;23(4):201–8.CrossRef
15.
Zurück zum Zitat Testa D, Filippini G, Farinotti M, Palazzini E, Caraceni T. Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol. 1996;243(5):401–4.CrossRefPubMed Testa D, Filippini G, Farinotti M, Palazzini E, Caraceni T. Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol. 1996;243(5):401–4.CrossRefPubMed
16.
Zurück zum Zitat Figueroa JJ, Singer W, Parsaik A, Benarroch EE, Ahlskog JE, Fealey RD, et al. Multiple system atrophy: prognostic indicators of survival. Mov Disord. 2014;29(9):1151–7.PubMedCentralCrossRefPubMed Figueroa JJ, Singer W, Parsaik A, Benarroch EE, Ahlskog JE, Fealey RD, et al. Multiple system atrophy: prognostic indicators of survival. Mov Disord. 2014;29(9):1151–7.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Wullner U, Schmitz-Hubsch T, Abele M, Antony G, Bauer P, Eggert K. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm. 2007;114(9):1161–5.CrossRefPubMed Wullner U, Schmitz-Hubsch T, Abele M, Antony G, Bauer P, Eggert K. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm. 2007;114(9):1161–5.CrossRefPubMed
18.
Zurück zum Zitat Hirayama K, Kita K. Clinical features of “multiple system atrophies”—olivo-ponto-cerebellar atrophy, striato-nigral degeneration and Shy-Drager syndrome. Rinsho Shinkeigaku. 1985;25(10):1196–203.PubMed Hirayama K, Kita K. Clinical features of “multiple system atrophies”—olivo-ponto-cerebellar atrophy, striato-nigral degeneration and Shy-Drager syndrome. Rinsho Shinkeigaku. 1985;25(10):1196–203.PubMed
19.
Zurück zum Zitat O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(Pt 5):1362–72.PubMed O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(Pt 5):1362–72.PubMed
20.
Zurück zum Zitat Tada M, Onodera O, Ozawa T, Piao YS, Kakita A, Takahashi H, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol. 2007;64(2):256–60.CrossRefPubMed Tada M, Onodera O, Ozawa T, Piao YS, Kakita A, Takahashi H, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol. 2007;64(2):256–60.CrossRefPubMed
Metadaten
Titel
Epidemiology of Multiple System Atrophy in Hokkaido, the Northernmost Island of Japan
verfasst von
Ken Sakushima
Naoki Nishimoto
Masanori Nojima
Masaaki Matsushima
Ichiro Yabe
Norihiro Sato
Mitsuru Mori
Hidenao Sasaki
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
The Cerebellum / Ausgabe 6/2015
Print ISSN: 1473-4222
Elektronische ISSN: 1473-4230
DOI
https://doi.org/10.1007/s12311-015-0668-6

Weitere Artikel der Ausgabe 6/2015

The Cerebellum 6/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.